10x Genomics, Inc. (NASDAQ:TXG) Q4 2021 Earnings Conference Call February 16, 2022 4:30 PM ET Company Participants Eric Jaschke - Director of IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Conference Call Participants Tycho Peterson - JPMorgan Derik De Bruin - Bank of America Dan Brennan - Cowen Tejas Savant - Morgan Stanley Patrick Donnelly - Citi Dan Arias - Stifel Matt Larew - William Blair Matt Sykes - Goldman Sachs Operator Hello, good afternoon, and welcome to the 10x ...

Mastering Biology to Advance Human Health Serge Saxonov, CEO and Co-founder GENOMICS © 10X GENOMICS, INC. 2022. 1 Disclaimer Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts may be f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Table of Contents OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR 10x Genomics, Inc. (Exact Name of Re ...

10x Genomics, Inc. (NASDAQ:TXG) Q2 2021 Earnings Conference Call August 4, 2021 4:30 PM ET Company Participants Eric Jaschke - Director of IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Brad Crutchfield - Chief Commercial Officer Conference Call Participants Doug Schenkel - Cowen & Company Tycho Peterson - JP Morgan Tejas Savant - Morgan Stanley Mike Ryskin - Bank of America David Westenberg - Guggenheim Securities Patrick Donnelly - Citi Matt Sykes - Goldman Sachs Matt Lar ...

Company Overview - 10x Genomics has over 2,400 installed instruments[6] - The company's consumable pull-through is over $150,000[6] - 10x Genomics holds over 1,100 patents and applications[6] - There are over 2,500 publications referencing 10x Genomics' technology[6] - Approximately 50% of sales are outside the US[15] Product Platforms and Market Opportunity - The company operates across three product platforms: Chromium Single Cell, Visium Spatial, and In Situ[26] - 10x Genomics addresses a global life science research tools market estimated at $15 billion[32, 33] - The company sees a downstream clinical applications market opportunity for In Situ analysis of $10 billion[35, 36] New Product Initiatives - The company launched the CellPlex Kit in Q1 2021, reducing all-in cost by approximately 60%[41, 56] - The Low Throughput Kit launched in Q2 2021, reducing startup cost by over 60%[44, 56] - Visium for FFPE is coming in Q2 2021, solving the challenge of FFPE samples[61]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of R ...

10x Genomics, Inc. (NASDAQ:TXG) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Eric Jaschke - Director of IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Brad Crutchfield - Chief Commercial Officer Conference Call Participants Doug Schenkel - Cowen & Company Tejas Savant - Morgan Stanley Patrick Donnelly - Citi Dan Arias - Stifel Nicolaus Matt Larew - William Blair Operator Ladies and gentlemen, thank you for standing by, and welcome to the 10x ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 10-K __________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of Registrant as Specif ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2020 Results Conference Call February 17, 2021 4:30 PM ET Company Participants Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Brad Crutchfield - Chief Commercial Officer Conference Call Participants Doug Schenkel - Cowen Tejas Savant - Morgan Stanley Derik De Bruin - Bank of America David Westenberg - Guggenheim Securities Dan Arias - Stifel Patrick Donnelly - Citi Matt Sykes - Goldman Sachs Operator Ladies and gentlemen, thank you for standing by and welcome to t ...